UK MHRA Accepts Ultragenyx Gene Therapy Application for Review

Bitget2026/11/06 08:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

UK MHRA accepted Ultragenyx's marketing application for UX111 gene therapy for Sanfilippo syndrome Type A for review on Oct. 28, 2026.
NICE's evaluation will align with the regulatory review, targeting an NHS funding decision close to potential approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060330OMX_____CNEWS_EN_GNW9871894_en) on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

UK MHRA Accepts Ultragenyx Gene Therapy Application for Review

You may also like

Crypto prices